Sigma Planning Corp Has $271,000 Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Sigma Planning Corp lessened its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 61.9% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 2,230 shares of the medical equipment provider’s stock after selling 3,620 shares during the period. Sigma Planning Corp’s holdings in Zimmer Biomet were worth $271,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the business. American Century Companies Inc. grew its holdings in shares of Zimmer Biomet by 21.2% during the third quarter. American Century Companies Inc. now owns 4,863,741 shares of the medical equipment provider’s stock worth $545,809,000 after purchasing an additional 852,186 shares during the last quarter. Victory Capital Management Inc. boosted its holdings in Zimmer Biomet by 4.9% in the third quarter. Victory Capital Management Inc. now owns 3,080,463 shares of the medical equipment provider’s stock valued at $345,690,000 after acquiring an additional 144,147 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in Zimmer Biomet by 16.3% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 2,760,021 shares of the medical equipment provider’s stock valued at $335,895,000 after acquiring an additional 386,019 shares during the last quarter. Boston Partners boosted its holdings in Zimmer Biomet by 29.2% in the third quarter. Boston Partners now owns 2,694,832 shares of the medical equipment provider’s stock valued at $302,366,000 after acquiring an additional 608,959 shares during the last quarter. Finally, Northern Trust Corp boosted its holdings in Zimmer Biomet by 4.5% in the third quarter. Northern Trust Corp now owns 2,653,334 shares of the medical equipment provider’s stock valued at $297,757,000 after acquiring an additional 113,139 shares during the last quarter. Institutional investors own 88.89% of the company’s stock.

Insider Activity at Zimmer Biomet

In related news, VP Chad F. Phipps sold 26,156 shares of Zimmer Biomet stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $128.62, for a total value of $3,364,184.72. Following the sale, the vice president now owns 44,145 shares of the company’s stock, valued at approximately $5,677,929.90. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.70% of the stock is owned by insiders.

Wall Street Analyst Weigh In

ZBH has been the topic of several recent research reports. Barclays raised their price target on Zimmer Biomet from $120.00 to $130.00 and gave the company an “underweight” rating in a report on Monday, February 12th. StockNews.com cut Zimmer Biomet from a “strong-buy” rating to a “buy” rating in a report on Monday, February 19th. Raymond James raised their price target on Zimmer Biomet from $133.00 to $137.00 and gave the company an “outperform” rating in a report on Wednesday, January 3rd. Citigroup increased their target price on Zimmer Biomet from $134.00 to $140.00 and gave the company a “neutral” rating in a research note on Wednesday, April 3rd. Finally, TheStreet raised Zimmer Biomet from a “c” rating to a “b-” rating in a research note on Thursday, February 8th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and six have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $139.39.

Zimmer Biomet Trading Down 0.3 %

NYSE ZBH opened at $119.35 on Monday. The firm has a market cap of $24.52 billion, a P/E ratio of 24.41, a P/E/G ratio of 2.19 and a beta of 1.01. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.61 and a quick ratio of 0.78. The stock’s 50-day moving average is $125.98 and its 200-day moving average is $119.67. Zimmer Biomet Holdings, Inc. has a one year low of $102.00 and a one year high of $149.25.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 EPS for the quarter, topping analysts’ consensus estimates of $2.15 by $0.05. Zimmer Biomet had a return on equity of 12.79% and a net margin of 13.85%. The company had revenue of $1.94 billion for the quarter, compared to analyst estimates of $1.93 billion. During the same quarter last year, the firm posted $1.88 earnings per share. Zimmer Biomet’s revenue was up 6.3% compared to the same quarter last year. Sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.07 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.80%. The ex-dividend date is Wednesday, March 27th. Zimmer Biomet’s dividend payout ratio is presently 19.63%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.